https://peptide.zone/story/lilly-hims-deal-zepbound-foundayoPeptide Zoneen2026-11-07T04:57:00.000ZLilly Hims deal puts Zepbound and Foundayo on telehealth at self pay prices https://peptide.zone/story/peptide-legal-risks-physicians-fda-pausePeptide Zoneen2026-11-07T04:25:00.000ZPeptide legal risks for physicians remain after FDA compounding pause https://peptide.zone/story/glp-1-medicaid-coverage-narrowsPeptide Zoneen2026-11-07T03:35:00.000ZGLP 1 Medicaid coverage narrows as heart and kidney evidence grows https://peptide.zone/story/orforglipron-sleep-apnea-trial-aha-late-breakerPeptide Zoneen2026-11-07T02:40:00.000ZOrforglipron sleep apnea trial ATTAIN OSA set for Monday AHA late breaker in Chicago https://peptide.zone/story/glp-1-allodynia-burning-skin-reportsPeptide Zoneen2026-11-06T04:27:00.000ZGLP 1 allodynia reports link weight loss drugs to burning skin pain https://peptide.zone/story/hhs-peptide-compounding-policy-evidence-questionsPeptide Zoneen2026-11-06T03:37:00.000ZHHS peptide compounding policy faces evidence questions before comment deadline https://peptide.zone/story/glp-1-side-effects-hair-loss-visionPeptide Zoneen2026-11-06T03:03:00.000ZGLP 1 side effects range from common hair loss to rare vision loss https://peptide.zone/story/rogaine-sales-30-percent-glp-1Peptide Zoneen2026-11-06T02:13:00.000ZRogaine sales up 30 percent this year as CEO links rise to GLP 1 drugs